ABSTRACT

Introduction

The Zilver PTX stent was the first self-expanding drug-coated stent approved by the United States Food and Drug Administration (US FDA) for use in the superficial femoral artery (SFA) above the knee. The main objective of this article is to review the design, safety, and efficacy of the Zilver PTX stent which was engineered to outperform bare metal stents (BMS) in this challenging environment.

Areas covered

An evaluation of the Zilver PTX peripheral paclitaxel-coated stent design and a review of the current preclinical and clinical evidence regarding the use of this stent.

Expert opinion

Stent implantation for the treatment of peripheral arterial disease (PAD) in the SFA was initially seen as a salvage option; however, stenting is now routinely offered as initial therapy for patients suffering from claudication and critical limb ischemia. The Zilver PTX stent has established efficacy and safety profiles for paclitaxel in the SFA; however, the development of biocompatible polymers capable of extending the elution time of anti-proliferative agents may lead to more effective stent platforms.

中文翻译：

---

Zilver PTX外周紫杉醇洗脱支架：一项技术评估。

摘要

介绍

Zilver PTX支架是美国食品和药物管理局（US FDA）批准的首个自扩张药物涂层支架，可用于膝盖以上的股浅动脉（SFA）。本文的主要目的是回顾Zilver PTX支架的设计，安全性和有效性，该Zilver PTX支架在这种充满挑战的环境中性能优于裸金属支架（BMS）。

覆盖区域

Zilver PTX外周紫杉醇涂层支架设计的评估，以及有关使用该支架的当前临床前和临床证据的综述。

专家意见

最初将支架植入术用于治疗SFA中的外周动脉疾病（PAD）是一种挽救选择；但是，现在对于患有c行和严重肢体缺血的患者，常规地提供支架治疗作为初始治疗。Zilver PTX支架已建立了SFA中紫杉醇的疗效和安全性；然而，能够延长抗增殖剂洗脱时间的生物相容性聚合物的开发可能会导致更有效的支架平台。